Cantor Fitzgerald Reiterates Neutral on Verve Therapeutics, Maintains $22 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Rick Bienkowski has reiterated a Neutral rating on Verve Therapeutics (NASDAQ:VERV) and maintained a $22 price target.
August 29, 2023 | 4:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating on Verve Therapeutics and maintained a $22 price target.
The reiteration of a Neutral rating and maintenance of the $22 price target by Cantor Fitzgerald indicates that the analyst sees no major changes in the company's outlook. This could mean that the stock price is expected to remain stable in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100